Xtant Medical (XTNT) 10-Q 1 Aug 23 2023 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2023	Jul. 28, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-34951
Entity Registrant Name	XTANT MEDICAL HOLDINGS, INC.
Entity Central Index Key	0001453593
Entity Tax Identification Number	20-5313323
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	664 Cruiser Lane
Entity Address, City or Town	Belgrade
Entity Address, State or Province	MT
Entity Address, Postal Zip Code	59714
City Area Code	(406)
Local Phone Number	388-0480
Title of 12(b) Security	Common stock, par value $0.000001 per share
Trading Symbol	XTNT
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		128,897,048

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 4,138	$ 20,298
Restricted cash	310	209
Trade accounts receivable, net of allowance for credit losses and doubtful accounts of $740 and $515, respectively	13,744	10,853
Inventories	20,364	17,285
Prepaid and other current assets	1,015	673
Total current assets	39,571	49,318
Property and equipment, net	6,875	5,785
Right-of-use asset, net	1,155	1,380
Goodwill	6,514	3,205
Intangible assets, net	10,920	344
Other assets	183	197
Total Assets	65,218	60,229
Current Liabilities:
Accounts payable	4,444	3,490
Accrued liabilities	6,255	5,496
Current portion of lease liability	488	458
Current portion of finance lease obligations	63	62
Line of credit	5,031	3,379
Current portion of long-term debt	708	2,333
Total current liabilities	16,989	15,218
Long-term Liabilities:
Lease liability, less current portion	720	972
Finance lease obligation, less current portion	149	181
Long-term debt, plus premium and less issuance costs	16,401	9,687
Total Liabilities	34,259	26,058
Commitments and Contingencies (note 13)
Stockholders’ Equity:
Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.000001 par value; 300,000,000 shares authorized; 108,897,048 shares issued and outstanding as of June 30, 2023 and 108,874,803 shares issued and outstanding as of December 31, 2022
Additional paid-in capital	278,897	277,841
Accumulated deficit	(247,938)	(243,670)
Total Stockholders’ Equity	30,959	34,171
Total Liabilities & Stockholders’ Equity	$ 65,218	$ 60,229

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Allowance of accounts receivable, net	$ 740	$ 515
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	108,897,048	108,874,803
Common stock, shares outstanding	108,897,048	108,874,803

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue
Orthopedic product sales	$ 20,232	$ 15,277	$ 38,175	$ 28,227
Other revenue			1	9
Total Revenue	20,232	15,277	38,176	28,236
Cost of sales	7,773	6,903	15,180	12,302
Gross Profit	12,459	8,374	22,995	15,934
Operating Expenses
General and administrative	4,954	3,797	9,839	7,766
Sales and marketing	8,716	5,636	15,770	10,845
Research and development	180	241	354	454
Total Operating Expenses	13,850	9,674	25,963	19,065
Loss from Operations	(1,391)	(1,300)	(2,967)	(3,131)
Other Expense
Interest expense	(786)	(397)	(1,360)	(757)
Interest income			85
Total Other Expense	(786)	(397)	(1,275)	(757)
Net Loss from Operations Before Provision for Income Taxes	(2,177)	(1,697)	(4,242)	(3,888)
Provision for Income Taxes Current and Deferred	(13)	(13)	(26)	(35)
Net Loss	$ (2,190)	$ (1,710)	$ (4,268)	$ (3,923)
Net Loss Per Share:
Basic	$ (0.02)	$ (0.02)	$ (0.04)	$ (0.04)
Dilutive	$ (0.02)	$ (0.02)	$ (0.04)	$ (0.04)
Shares used in the computation:
Basic	108,897,048	87,313,701	108,895,327	87,252,521
Dilutive	108,897,048	87,313,701	108,895,327	87,252,521

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Balance at Dec. 31, 2021	$ 30,883		$ 266,068	$ (235,185)
Balance, shares at Dec. 31, 2021		87,068,980
Common stock issued on vesting of restricted stock units
Common stock issued on vesting of restricted stock units, shares		244,721
Stock-based compensation	613		613
Net loss	(2,213)			(2,213)
Balance at Mar. 31, 2022	29,283		266,681	(237,398)
Balance, shares at Mar. 31, 2022		87,313,701
Balance at Dec. 31, 2021	30,883		266,068	(235,185)
Balance, shares at Dec. 31, 2021		87,068,980
Net loss	(3,923)
Balance at Jun. 30, 2022	28,144		267,252	(239,108)
Balance, shares at Jun. 30, 2022		87,313,701
Balance at Mar. 31, 2022	29,283		266,681	(237,398)
Balance, shares at Mar. 31, 2022		87,313,701
Stock-based compensation	571		571
Net loss	(1,710)			(1,710)
Balance at Jun. 30, 2022	28,144		267,252	(239,108)
Balance, shares at Jun. 30, 2022		87,313,701
Balance at Dec. 31, 2022	34,171		277,841	(243,670)
Balance, shares at Dec. 31, 2022		108,874,803
Common stock issued on vesting of restricted stock units
Common stock issued on vesting of restricted stock units, shares		22,245
Stock-based compensation	617		617
Net loss	(2,078)			(2,078)
Balance at Mar. 31, 2023	32,710		278,458	(245,748)
Balance, shares at Mar. 31, 2023		108,897,048
Balance at Dec. 31, 2022	34,171		277,841	(243,670)
Balance, shares at Dec. 31, 2022		108,874,803
Net loss	(4,268)
Balance at Jun. 30, 2023	30,959		278,897	(247,938)
Balance, shares at Jun. 30, 2023		108,897,048
Balance at Mar. 31, 2023	32,710		278,458	(245,748)
Balance, shares at Mar. 31, 2023		108,897,048
Stock-based compensation	439		439
Net loss	(2,190)			(2,190)
Balance at Jun. 30, 2023	$ 30,959		$ 278,897	$ (247,938)
Balance, shares at Jun. 30, 2023		108,897,048

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Operating activities:
Net loss	$ (4,268)	$ (3,923)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,274	599
Gain on disposal of fixed assets	(21)	(84)
Non-cash interest	189	116
Non-cash rent	3	(1)
Stock-based compensation	1,056	1,184
Provision for reserve on accounts receivable	225	143
Provision for excess and obsolete inventory	243	825
Changes in operating assets and liabilities, net of the effects of the acquisition:
Accounts receivable	(3,116)	(1,589)
Inventories	(1,733)	659
Prepaid and other assets	(330)	465
Accounts payable	954	428
Accrued liabilities	758	189
Net cash used in operating activities	(4,766)	(989)
Investing activities:
Purchases of property and equipment and intangible assets	(870)	(810)
Proceeds from sale of fixed assets	55	165
Acquisition of Surgalign SPV, Inc.	(17,000)
Net cash used in investing activities	(17,815)	(645)
Financing activities:
Payments on financing leases	(30)	(22)
Borrowings on line of credit	36,256	26,567
Repayments on line of credit	(34,603)	(26,451)
Net proceeds from issuance of long-term debt, net of issuance costs	4,899
Net cash provided by financing activities	6,522	94
Net change in cash and cash equivalents and restricted cash	(16,059)	(1,540)
Cash and cash equivalents and restricted cash at beginning of period	20,507	18,387
Cash and cash equivalents and restricted cash at end of period	4,448	16,847
Reconciliation of cash and cash equivalents and restricted cash reported in the condensed consolidated balance sheets
Cash and cash equivalents	4,138	16,495
Restricted cash	310	352
Total cash and restricted cash reported in condensed consolidated balance sheets	$ 4,448	$ 16,847

Business Description, Basis of

Business Description, Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description, Basis of Presentation and Summary of Significant Accounting Policies	(1) Business Description, Basis of Presentation and Summary of Significant Accounting Policies Business Description and Basis of Presentation The accompanying condensed consolidated financial statements include the accounts of Xtant Medical Holdings, Inc. (“Xtant”), a Delaware corporation, and its wholly owned subsidiaries, Xtant Medical, Inc. (“Xtant Medical”), a Delaware corporation, Bacterin International, Inc. (“Bacterin”), a Nevada corporation, Surgalign SPV, Inc., a Delaware corporation, and X-spine Systems, Inc. (“X-spine”), an Ohio corporation (Xtant, Xtant Medical, Bacterin, Surgalign SPV, Inc. and X-spine are jointly referred to herein as the “Company” or sometimes “we,” “our,” or “us”). All intercompany balances and transactions have been eliminated in consolidation. Xtant is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. The accompanying condensed consolidated balance sheet as of December 31, 2022, which has been derived from audited financial statements, and the unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. They do not include all disclosures required by generally accepted accounting principles for annual consolidated financial statements, but in the opinion of management include all adjustments, consisting only of normal recurring items, necessary for a fair presentation. Interim results are not necessarily indicative of results that may be achieved in the future for the full year ending December 31, 2023. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto, which are included in Xtant’s Annual Report on Form 10-K for the year ended December 31, 2022. The accounting policies set forth in those annual consolidated financial statements are the same as the accounting policies utilized in the preparation of these condensed consolidated financial statements, except as modified for appropriate interim consolidated financial statement presentation. Use of Estimates The preparation of the condensed consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the period. Significant estimates include the carrying amount of property and equipment; goodwill, intangible assets and liabilities; valuation allowances for trade receivables, inventory, deferred income tax assets and liabilities; current and long-term lease obligations and corresponding right-of-use asset; estimates for the fair value of assets acquired as part of business combinations; and estimates for the fair value of long-term debt, stock options and other equity awards upon which the Company determines stock-based compensation expense. Actual results could differ from those estimates. Restricted Cash Cash and cash equivalents classified as restricted cash on our condensed consolidated balance sheets are restricted as to withdrawal or use under the terms of certain contractual agreements. The June 30, 2023 and December 31, 2022 balances included lockbox deposits that are temporarily restricted due to timing at the period end. The lockbox deposits are applied against our line of credit the next business day. Concentration of Credit Risk Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains its cash balances primarily with two financial institutions. These balances generally exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in cash and cash equivalents. Long-Lived Assets The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recovered. No Goodwill Goodwill represents the excess of costs over fair value of assets of businesses acquired. Goodwill and intangible assets acquired in a purchase business combination and determined to have indefinite useful lives are not amortized. Instead, they are tested for impairment at least annually, and whenever events or circumstances indicate, the carrying amount of the asset may not be recoverable. No Net Loss Per Share Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted net loss per share is computed in a manner consistent with that of basic earnings per share while giving effect to all potentially dilutive shares of common stock outstanding during the period, which include the assumed exercise of stock options and warrants using the treasury stock method. Diluted net loss per share was the same as basic net loss per share for the three and six months ended June 30, 2023 and 2022, as shares issuable upon the exercise of stock options and warrants were anti-dilutive as a result of the net losses incurred for those periods. Our diluted earnings per share is the same as basic earnings per share, as the effects of including 18,885,572 12,474,376 Fair Value of Financial Instruments The carrying values of financial instruments, including trade accounts receivable, accounts payable, accrued liabilities, and long-term debt, approximate their fair values based on terms and related interest rates as of June 30, 2023 and December 31, 2022.

Acquisition of Coflex and CoFix

Acquisition of Coflex and CoFix Product Lines	6 Months Ended
	Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]
Acquisition of Coflex and CoFix Product Lines	(2) Acquisition of Coflex and CoFix Product Lines On February 28, 2023, we entered into an Equity Purchase Agreement (the “Equity Purchase Agreement”) with Surgalign SPV, Inc., a wholly owned subsidiary of Surgalign Spine Technologies, Inc., (“Seller”), Seller and Surgalign Holdings, Inc., pursuant to which we purchased all of the issued and outstanding shares of common stock of Surgalign SPV, which shares constituted all of the outstanding equity of Surgalign SPV, for an aggregate purchase price of $ 17.0 Immediately prior to the Closing, Seller and its affiliates transferred and assigned to Surgalign SPV, a newly formed entity wholly owned by Seller, certain intellectual property, contractual rights and other assets related to the design, manufacture, sale and distribution of Seller’s Coflex and CoFix products in the United States (the “Coflex Business”). The Coflex and CoFix products have been approved by the U.S. Food and Drug Administration for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression and provide minimally invasive, motion preserving stabilization. In conjunction with the Equity Purchase Agreement, on February 28, 2023, we entered into a Transition Services Agreement with Surgalign SVP and Seller, whereby Seller agreed to provide, or cause to be provided, to us on and after the effective date of the Equity Purchase Agreement, after giving effect to the Closing, certain transitional services related to the transition of the Coflex Business. We funded the Purchase Price with cash on hand and approximately $ 5.0 We recorded the purchase of this acquisition using the acquisition method of accounting and, accordingly, recognized the assets acquired at their fair values as of the date of acquisition. The valuation of the acquired assets was refined during the three months ended June 30, 2023 resulting in adjustments to our allocation of the purchase price for additional inventory of $ 0.5 0.5 Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Inventories $ 1,589 Equipment 947 Intangible assets 11,155 Net assets acquired 13,691 Goodwill 3,309 Total purchase consideration $ 17,000 The acquisition was recorded by allocating the costs of the net assets acquired based on their estimated fair values at the acquisition date. The fair values were based on management’s analysis, including work performed by third-party valuation specialists. Management’s estimates and assumptions are subject to change during the measurement period (up to one year from the acquisition date) as we finalize our valuations of assets acquired and liabilities assumed in connection with the acquisition. The primary areas of the purchase price allocation that are not yet finalized relate to identifiable intangible assets and goodwill. The acquisition strengthened the Company’s spine portfolio with the addition of the Coflex Business. Coflex is a differentiated and minimally invasive motion preserving stabilization implant that is FDA PMA-approved for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression. This potential benefit resulted in the Company paying a premium for the acquisition resulting in the recognition of $ 3.3 The following unaudited pro forma combined financial information summarizes the results of operations for the periods indicated as if the acquisition had been completed as of January 1, 2022 (in thousands): Schedule of Pro forma Financial Information of Operations Six Months Ended June 30, 2023 2022 Revenues $ 40,000 $ 31,828 Net loss (3,745 ) (2,543 ) Pro forma information reflects adjustments that are expected to have a continuing impact on our results of operations and are directly attributable to the acquisition. The unaudited pro forma results include adjustments to reflect the amortization of the inventory step-up and the incremental intangible asset amortization to be incurred based on the preliminary values of each identifiable intangible asset. The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the acquisition had occurred as of January 1, 2022 or that may be obtained in the future, and do not reflect future synergies, integration costs, or other such costs or savings.

Asset Purchase Agreement

Asset Purchase Agreement	6 Months Ended
	Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]
Asset Purchase Agreement	(3) Asset Purchase Agreement As previously disclosed, on June 18, 2023, we entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Surgalign Holdings, Inc. (“Surgalign Holdings”), pursuant to which, subject to the terms and conditions set forth in the Asset Purchase Agreement, we agreed to acquire certain assets of Surgalign Holdings and its subsidiaries on an as-is, where-is basis, including specified inventory, intellectual property and intellectual property rights, contracts, records and all outstanding equity securities of its international subsidiaries, and intangibles related to the business of designing, developing and manufacturing hardware medical technology and distributing biologics medical technology, as conducted by Surgalign Holdings and its subsidiaries (collectively, the “Assets”), and assume certain specified liabilities of Surgalign Holdings and its subsidiaries (collectively, the “Liabilities” and such acquisition of the Assets and assumption of the Liabilities together, the “Transaction”) for a total purchase price of $ 5 10 Surgalign Holdings, together with certain of its subsidiaries, is a debtor in a voluntary Chapter 11 case before the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”), which commenced on June 19, 2023, and therefore, the Transaction is being conducted through a Bankruptcy Court-supervised process and is subject to approval of the sale by the Bankruptcy Court and the satisfaction of certain conditions. Following Bankruptcy Court approval, we were designated as the initial bidder in connection with a sale of the Assets under Section 363 of the Bankruptcy Code. On July 28, 2023, the Seller filed a Notice of Successful Bidder announcing the Company as the successful bidder in an auction conducted under Bankruptcy-court approved bidding procedures. Pursuant to the terms of the Asset Purchase Agreement, and pending the issuance of a Sale Order by the Bankruptcy Court, closing of the Transaction is expected to occur after the Bankruptcy Court sale hearing, scheduled for August 8, 2023, but in no event later than September 1, 2023.

Revenue

Revenue	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue	(4) Revenue In the United States, we generate most of our revenue from independent commissioned sales agents. We consign our orthobiologics products to hospitals and consign or loan our spinal implant sets to the independent sales agents. The spinal implant sets typically contain the instruments, disposables, and spinal implants required to complete a surgery. Consigned sets are managed by the sales agent to service hospitals that are high volume users for multiple procedures. We ship replacement inventory to independent sales agents to replace the consigned inventory used in surgeries. Loaned sets are returned to the Company’s distribution center, replenished, and made available to sales agents for the next surgical procedure. For each surgical procedure, the sales agent reports use of the product by the hospital and, as soon as practicable thereafter, ensures that the hospital provides a purchase order to the Company. Revenue is recognized upon utilization of product. Additionally, the Company sells product directly to domestic and international stocking resellers and private label resellers. Upon receipt and acceptance of a purchase order from a stocking reseller, the Company ships product and invoices the reseller. The Company recognizes revenue when control of the promised goods is transferred to the customer, in an amount that reflects the consideration the Company expects to collect in exchange for those goods or services. There is generally no customer acceptance or other condition that prevents the Company from recognizing revenue in accordance with the delivery terms for these sales transactions. The Company operates in one reportable segment with our net revenue derived primarily from the sale of orthobiologics and spinal implant products across North America, Europe, Asia Pacific, and Latin America. Sales are reported net of returns. The following table presents revenues from these product lines for the three and six months ended June 30, 2023 and 2022 (in thousands): Summary of Revenues from Product Lines Three Months Ended Percentage of Three Months Ended Percentage of June 30, 2023 Total Revenue June 30, 2022 Total Revenue Orthobiologics $ 14,315 71 % $ 12,402 81 % Spinal implant 5,917 29 % 2,875 19 % Other revenue — 0 % — 0 % Total revenue $ 20,232 100 % $ 15,277 100 % Six Months Ended Percentage of Six Months Percentage of June 30, 2023 Total Revenue June 30, 2022 Total Revenue Orthobiologics $ 27,866 73 % $ 22,568 80 % Spinal implant 10,309 27 % 5,659 20 % Other revenue 1 0 % 9 0 % Total revenue $ 38,176 100 % $ 28,236 100 %

Receivables

Receivables	6 Months Ended
	Jun. 30, 2023
Credit Loss [Abstract]
Receivables	(5) Receivables The Company’s provision for current expected credit loss is determined based on historical collection experience adjusted for current economic conditions affecting collectability. Actual customer collections could differ from estimates. Account balances are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Provisions to the allowance for credit losses are charged to expense. Activity within the allowance for credit losses was as follows for the three months and six months ended June 30, 2023 and 2022 (in thousands): Schedule of Allowance for Credit Losses June 30, 2023 June 30, 2022 Balance at January 1 $ 515 $ 552 Provision for expected credit losses 106 191 Write-offs charged against allowance — (173 ) Balance at March 31 621 570 Provision for expected credit losses 119 (49 ) Write-offs charged against allowance — (11 ) Balance at June 30 $ 740 $ 510

Inventories

Inventories	6 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Inventories	(6) Inventories Inventories consist of the following (in thousands): Schedule of Inventories June 30, 2023 December 31, 2022 Raw materials $ 6,359 $ 5,628 Work in process 1,406 798 Finished goods 12,599 10,859 Total $ 20,364 $ 17,285

Property and Equipment, Net

Property and Equipment, Net	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	(7) Property and Equipment, Net Property and equipment, net are as follows (in thousands): Schedule of Property and Equipment, Net June 30, 2023 December 31, 2022 Equipment $ 5,597 $ 5,598 Computer equipment 1,158 1,043 Computer software 230 230 Leasehold improvements 4,105 4,105 Surgical instruments 12,209 11,266 Assets not yet in service 2,079 1,507 Total cost 25,378 23,749 Property and equipment, gross 25,378 23,749 Less: accumulated depreciation (18,503 ) (17,964 ) Property and equipment, net $ 6,875 $ 5,785 Depreciation expense related to property and equipment, including property under finance leases, for the three months ended June 30, 2023 and 2022 was $ 0.4 0.3 0.7 0.6

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	(8) Intangible Assets The following table sets forth information regarding intangible assets based on the preliminary purchase accounting discussed in Note 2 – Acquisition of Coflex and CoFix Product Lines (in thousands): Schedule of Intangible of Assets June 30, 2023 December 31, 2022 Patents $ 2,617 $ 807 Customer relationships 8,100 — Trade names 1,245 — Total cost 11,962 807 Intangible assets, gross 11,962 807 Less: accumulated amortization (1,042 ) (463 ) Intangible assets, net $ 10,920 $ 344

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2023
Payables and Accruals [Abstract]
Accrued Liabilities	(9) Accrued Liabilities Accrued liabilities consist of the following (in thousands): Schedule of Accrued Liabilities June 30, 2023 December 31, 2022 Cash compensation/commissions payable $ 5,455 $ 4,464 Other accrued liabilities 800 1,032 Accrued liabilities $ 6,255 $ 5,496

Debt

Debt	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Debt	(10) Debt Long-term debt consists of the following (in thousands): Schedule of Long-term Debt June 30, 2023 December 31, 2022 Amounts due under the term loan $ 17,000 $ 12,000 Accrued end-of-term payments 337 216 Less: unamortized debt issuance costs (228 ) (196 ) Less: current maturities (708 ) (2,333 ) Long-term debt, less issuance costs $ 16,401 $ 9,687 On February 28, 2023, the Company’s term loan agreement was amended to provide an additional $ 5.0 1 2.5 In May 2023, the Company extended its interest only period on the term loan until June 2024 when the Company is required to make monthly principal payments of approximately $ 0.7 The effective rate of the term loan, inclusive of amortization of debt issuance costs and accretion of the final payment, was 13.79 9.77 3.0

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	(11) Stock-Based Compensation Stock option activity, including options granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended (the “2018 Plan”), and the Amended and Restated Xtant Medical Equity Incentive Plan and options granted to new hires to purchase shares of our common stock outside of any stockholder-approved plan, was as follows for the six months ended June 30, 2023 and 2022: Schedule of Share-based Compensation, Stock Options Activity 2023 2022 Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (years) Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (years) Outstanding at January 1 3,360,664 $ 1.51 3,201,666 $ 1.80 Granted 130,000 0.74 109,164 0.65 Cancelled or expired (75,460 ) $ 18.61 (443,125 ) $ 2.39 Outstanding at June 30 3,415,204 $ 1.49 7.7 2,867,705 $ 1.66 8.4 Exercisable at June 30 1,438,894 $ 1.93 7.3 599,063 $ 2.71 7.8 As of June 30, 2023, there was approximately $ 1.5 2.0 years. The weighted average grant date fair value of options granted during the three months ended June 30, 2023 was $ 0.61 . Restricted stock unit activity for awards granted under the 2018 Plan was as follows for the six months ended June 30, 2023 and 2022: Schedule of Restricted Stock Activity 2023 2022 Shares Weighted Average Value at Date Per Share Shares Weighted Average Value at Date Per Outstanding at January 1 3,612,433 $ 0.88 2,970,104 $ 1.39 Granted 186,831 $ 0.71 88,983 $ 0.65 Vested (22,245 ) $ 0.65 (244,721 ) $ 1.45 Cancelled (494,121 ) $ 0.54 (318,807 ) $ 1.32 Outstanding at June 30 3,282,898 $ 0.92 2,495,559 $ 1.36 Total compensation expense related to unvested restricted stock units not yet recognized was $ 2.0 2.0 On July 26, 2023, our stockholders approved and adopted the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan (the “2023 Plan”), which replaced the 2018 Plan with respect to future grants of equity awards, although the 2018 Plan continues to govern equity awards granted under the 2018 Plan. The 2023 Plan permits the Board of Directors, or a committee thereof, to grant to eligible employees, non-employee directors, and consultants of the Company non-statutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units, deferred stock units, performance awards, non-employee director awards, and other stock-based awards. The Board of Directors may select 2023 Plan participants and determine the nature and amount of awards to be granted. The maximum number of shares of our common stock available for issuance under the 2023 Plan, subject to adjustment pursuant to the terms of the 2023 Plan, is (i) 5,500,000 7,695,812 6,686,090

Warrants

Warrants	6 Months Ended
	Jun. 30, 2023
Warrants
Warrants	(12) Warrants As of June 30, 2023 and December 31, 2022, there were outstanding and exercisable warrants to purchase 12,187,470 1.53 3.3

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(13) Commitments and Contingencies Operating Leases We lease three office facilities as of June 30, 2023 in Belgrade, Montana under non-cancelable operating lease agreements with expiration dates in 2025. We have the option to extend certain leases for additional five or ten-year term(s), and we have the right of first refusal on any sale. As of June 30, 2023, the weighted-average remaining lease term was 2.3 Future minimum payments for the next five years and thereafter as of June 30, 2023 under these long-term operating leases are as follows (in thousands): Schedule of Future Minimum Rental Payments for Operating Leases Remainder of 2023 $ 271 2024 559 2025 470 Total future minimum lease payments 1,300 Less amount representing interest (92 ) Present value of obligations under operating leases 1,208 Less current portion (488 ) Long-term operating lease obligations $ 720 Rent expense was $ 0.1 0.3 Litigation We are subject to potential liabilities under government regulations and various claims and legal actions that are pending or may be asserted from time to time. These matters arise in the ordinary course and conduct of our business and may include, for example, commercial, product liability, intellectual property, and employment matters. We intend to continue to defend the Company vigorously in such matters and, when warranted, take legal action against others. Furthermore, we regularly assess contingencies to determine the degree of probability and range of possible loss for potential accrual in our financial statements. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on our assessment, we have adequately accrued an amount for contingent liabilities currently in existence. We do not accrue amounts for liabilities that we do not believe are probable or that we consider immaterial to our overall financial position. Litigation is inherently unpredictable, and unfavorable resolutions could occur. As a result, assessing contingencies is highly subjective and requires judgment about future events. While we do not believe that the ultimate resolution of any claims and lawsuits will have a material adverse effect upon our consolidated financial position, results of operations or cash flows, it is possible that the amount of ultimate loss may exceed our current accruals and that our cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of one or more of these contingencies. Indemnification Arrangements Our indemnification arrangements generally include limited warranties and certain provisions for indemnifying customers against liabilities if our products or services infringe a third-party’s intellectual property rights. To date, we have not incurred any material costs as a result of such warranties or indemnification provisions and have not accrued any liabilities related to such obligations in the accompanying condensed consolidated financial statements. We have also agreed to indemnify our directors and executive officers for costs associated with any fees, expenses, judgments, fines, and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by us, arising out of that person’s services as our director or officer or that person’s services provided to any other company or enterprise at our request.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	(14) Income Taxes In evaluating the realizability of the net deferred tax assets, we take into account a number of factors, primarily relating to the ability to generate taxable income. Where it is determined that it is likely that we will be unable to realize deferred tax assets, a valuation allowance is established against the portion of the deferred tax asset. Because it cannot be accurately determined when or if we will become profitable, a valuation allowance was provided against the entire deferred income tax asset balance. The Company did not recognize any interest or penalties related to income taxes for the three and six months ended June 30, 2023 and 2022.

Supplemental Disclosure of Cash

Supplemental Disclosure of Cash Flow Information	6 Months Ended
	Jun. 30, 2023
Supplemental Cash Flow Elements [Abstract]
Supplemental Disclosure of Cash Flow Information	(15) Supplemental Disclosure of Cash Flow Information Supplemental cash flow information is as follows (in thousands): Schedule of Supplemental Cash Flow Information 2023 2022 Six Months Ended June 30, 2023 2022 Supplemental disclosure of cash flow information Cash paid during the period for: Interest $ 1,171 $ 667 Non-cash activities: Fixed assets acquired under finance lease $ — $ 159

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	(16) Related Party Transactions As described in more detail under Note 1 – Business Description and Summary of Significant Accounting Policies in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 and Item 5 of Part II of this Quarterly Report on Form 10-Q, we are party to an Investor Rights Agreement, Registration Rights Agreements and certain other agreements with OrbiMed Royalty Opportunities II, LP (“Royalty Opportunities”) and ROS Acquisition Offshore LP (“ROS”), which are funds affiliated with OrbiMed Advisors LLC (“OrbiMed”). OrbiMed beneficially owns 67 All related party transactions are reviewed and approved by the Audit Committee or the disinterested members of the full Board of Directors.

Segment and Geographic Informat

Segment and Geographic Information	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Segment and Geographic Information	(17) Segment and Geographic Information The Company’s management reviews financial results and manages the business on an aggregate basis. Therefore, financial results are reported in a single operating segment: the development, manufacture, and marketing of orthopedic medical products and devices. The Company attributes revenues to geographic areas based on the location of the customer. Approximately 99 99 Schedule of Revenues by Geographic Region 2023 2022 Three Months Ended June 30, 2023 2022 United States $ 19,987 $ 15,025 Rest of world 245 252 Total revenue $ 20,232 $ 15,277 2023 2022 Six Months Ended June 30, 2023 2022 United States $ 37,501 $ 27,719 Rest of world 675 517 Total revenue $ 38,176 $ 28,236

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Event	(18) Subsequent Event On July 3, 2023, we entered into a securities purchase agreement pursuant to which we issued an aggregate of 20,000,000 0.75 15.0

Business Description, Basis o_2

Business Description, Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description and Basis of Presentation	Business Description and Basis of Presentation The accompanying condensed consolidated financial statements include the accounts of Xtant Medical Holdings, Inc. (“Xtant”), a Delaware corporation, and its wholly owned subsidiaries, Xtant Medical, Inc. (“Xtant Medical”), a Delaware corporation, Bacterin International, Inc. (“Bacterin”), a Nevada corporation, Surgalign SPV, Inc., a Delaware corporation, and X-spine Systems, Inc. (“X-spine”), an Ohio corporation (Xtant, Xtant Medical, Bacterin, Surgalign SPV, Inc. and X-spine are jointly referred to herein as the “Company” or sometimes “we,” “our,” or “us”). All intercompany balances and transactions have been eliminated in consolidation. Xtant is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. The accompanying condensed consolidated balance sheet as of December 31, 2022, which has been derived from audited financial statements, and the unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. They do not include all disclosures required by generally accepted accounting principles for annual consolidated financial statements, but in the opinion of management include all adjustments, consisting only of normal recurring items, necessary for a fair presentation. Interim results are not necessarily indicative of results that may be achieved in the future for the full year ending December 31, 2023. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto, which are included in Xtant’s Annual Report on Form 10-K for the year ended December 31, 2022. The accounting policies set forth in those annual consolidated financial statements are the same as the accounting policies utilized in the preparation of these condensed consolidated financial statements, except as modified for appropriate interim consolidated financial statement presentation.
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the period. Significant estimates include the carrying amount of property and equipment; goodwill, intangible assets and liabilities; valuation allowances for trade receivables, inventory, deferred income tax assets and liabilities; current and long-term lease obligations and corresponding right-of-use asset; estimates for the fair value of assets acquired as part of business combinations; and estimates for the fair value of long-term debt, stock options and other equity awards upon which the Company determines stock-based compensation expense. Actual results could differ from those estimates.
Restricted Cash	Restricted Cash Cash and cash equivalents classified as restricted cash on our condensed consolidated balance sheets are restricted as to withdrawal or use under the terms of certain contractual agreements. The June 30, 2023 and December 31, 2022 balances included lockbox deposits that are temporarily restricted due to timing at the period end. The lockbox deposits are applied against our line of credit the next business day.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains its cash balances primarily with two financial institutions. These balances generally exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in cash and cash equivalents.
Long-Lived Assets	Long-Lived Assets The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recovered. No
Goodwill	Goodwill Goodwill represents the excess of costs over fair value of assets of businesses acquired. Goodwill and intangible assets acquired in a purchase business combination and determined to have indefinite useful lives are not amortized. Instead, they are tested for impairment at least annually, and whenever events or circumstances indicate, the carrying amount of the asset may not be recoverable. No
Net Loss Per Share	Net Loss Per Share Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted net loss per share is computed in a manner consistent with that of basic earnings per share while giving effect to all potentially dilutive shares of common stock outstanding during the period, which include the assumed exercise of stock options and warrants using the treasury stock method. Diluted net loss per share was the same as basic net loss per share for the three and six months ended June 30, 2023 and 2022, as shares issuable upon the exercise of stock options and warrants were anti-dilutive as a result of the net losses incurred for those periods. Our diluted earnings per share is the same as basic earnings per share, as the effects of including 18,885,572 12,474,376
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying values of financial instruments, including trade accounts receivable, accounts payable, accrued liabilities, and long-term debt, approximate their fair values based on terms and related interest rates as of June 30, 2023 and December 31, 2022.

Acquisition of Coflex and CoF_2

Acquisition of Coflex and CoFix Product Lines (Tables)	6 Months Ended
	Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Inventories $ 1,589 Equipment 947 Intangible assets 11,155 Net assets acquired 13,691 Goodwill 3,309 Total purchase consideration $ 17,000
Schedule of Pro forma Financial Information of Operations	The following unaudited pro forma combined financial information summarizes the results of operations for the periods indicated as if the acquisition had been completed as of January 1, 2022 (in thousands): Schedule of Pro forma Financial Information of Operations Six Months Ended June 30, 2023 2022 Revenues $ 40,000 $ 31,828 Net loss (3,745 ) (2,543 )

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Summary of Revenues from Product Lines	Summary of Revenues from Product Lines Three Months Ended Percentage of Three Months Ended Percentage of June 30, 2023 Total Revenue June 30, 2022 Total Revenue Orthobiologics $ 14,315 71 % $ 12,402 81 % Spinal implant 5,917 29 % 2,875 19 % Other revenue — 0 % — 0 % Total revenue $ 20,232 100 % $ 15,277 100 % Six Months Ended Percentage of Six Months Percentage of June 30, 2023 Total Revenue June 30, 2022 Total Revenue Orthobiologics $ 27,866 73 % $ 22,568 80 % Spinal implant 10,309 27 % 5,659 20 % Other revenue 1 0 % 9 0 % Total revenue $ 38,176 100 % $ 28,236 100 %

Receivables (Tables)

Receivables (Tables)	6 Months Ended
	Jun. 30, 2023
Credit Loss [Abstract]
Schedule of Allowance for Credit Losses	Schedule of Allowance for Credit Losses June 30, 2023 June 30, 2022 Balance at January 1 $ 515 $ 552 Provision for expected credit losses 106 191 Write-offs charged against allowance — (173 ) Balance at March 31 621 570 Provision for expected credit losses 119 (49 ) Write-offs charged against allowance — (11 ) Balance at June 30 $ 740 $ 510

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of the following (in thousands): Schedule of Inventories June 30, 2023 December 31, 2022 Raw materials $ 6,359 $ 5,628 Work in process 1,406 798 Finished goods 12,599 10,859 Total $ 20,364 $ 17,285

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net are as follows (in thousands): Schedule of Property and Equipment, Net June 30, 2023 December 31, 2022 Equipment $ 5,597 $ 5,598 Computer equipment 1,158 1,043 Computer software 230 230 Leasehold improvements 4,105 4,105 Surgical instruments 12,209 11,266 Assets not yet in service 2,079 1,507 Total cost 25,378 23,749 Property and equipment, gross 25,378 23,749 Less: accumulated depreciation (18,503 ) (17,964 ) Property and equipment, net $ 6,875 $ 5,785

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible of Assets	The following table sets forth information regarding intangible assets based on the preliminary purchase accounting discussed in Note 2 – Acquisition of Coflex and CoFix Product Lines (in thousands): Schedule of Intangible of Assets June 30, 2023 December 31, 2022 Patents $ 2,617 $ 807 Customer relationships 8,100 — Trade names 1,245 — Total cost 11,962 807 Intangible assets, gross 11,962 807 Less: accumulated amortization (1,042 ) (463 ) Intangible assets, net $ 10,920 $ 344

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2023
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in thousands): Schedule of Accrued Liabilities June 30, 2023 December 31, 2022 Cash compensation/commissions payable $ 5,455 $ 4,464 Other accrued liabilities 800 1,032 Accrued liabilities $ 6,255 $ 5,496

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt consists of the following (in thousands): Schedule of Long-term Debt June 30, 2023 December 31, 2022 Amounts due under the term loan $ 17,000 $ 12,000 Accrued end-of-term payments 337 216 Less: unamortized debt issuance costs (228 ) (196 ) Less: current maturities (708 ) (2,333 ) Long-term debt, less issuance costs $ 16,401 $ 9,687

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Share-based Compensation, Stock Options Activity	Schedule of Share-based Compensation, Stock Options Activity 2023 2022 Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (years) Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (years) Outstanding at January 1 3,360,664 $ 1.51 3,201,666 $ 1.80 Granted 130,000 0.74 109,164 0.65 Cancelled or expired (75,460 ) $ 18.61 (443,125 ) $ 2.39 Outstanding at June 30 3,415,204 $ 1.49 7.7 2,867,705 $ 1.66 8.4 Exercisable at June 30 1,438,894 $ 1.93 7.3 599,063 $ 2.71 7.8
Schedule of Restricted Stock Activity	Restricted stock unit activity for awards granted under the 2018 Plan was as follows for the six months ended June 30, 2023 and 2022: Schedule of Restricted Stock Activity 2023 2022 Shares Weighted Average Value at Date Per Share Shares Weighted Average Value at Date Per Outstanding at January 1 3,612,433 $ 0.88 2,970,104 $ 1.39 Granted 186,831 $ 0.71 88,983 $ 0.65 Vested (22,245 ) $ 0.65 (244,721 ) $ 1.45 Cancelled (494,121 ) $ 0.54 (318,807 ) $ 1.32 Outstanding at June 30 3,282,898 $ 0.92 2,495,559 $ 1.36

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	Future minimum payments for the next five years and thereafter as of June 30, 2023 under these long-term operating leases are as follows (in thousands): Schedule of Future Minimum Rental Payments for Operating Leases Remainder of 2023 $ 271 2024 559 2025 470 Total future minimum lease payments 1,300 Less amount representing interest (92 ) Present value of obligations under operating leases 1,208 Less current portion (488 ) Long-term operating lease obligations $ 720

Supplemental Disclosure of Ca_2

Supplemental Disclosure of Cash Flow Information (Tables)	6 Months Ended
	Jun. 30, 2023
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Cash Flow Information	Supplemental cash flow information is as follows (in thousands): Schedule of Supplemental Cash Flow Information 2023 2022 Six Months Ended June 30, 2023 2022 Supplemental disclosure of cash flow information Cash paid during the period for: Interest $ 1,171 $ 667 Non-cash activities: Fixed assets acquired under finance lease $ — $ 159

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Schedule of Revenues by Geographic Region	Schedule of Revenues by Geographic Region 2023 2022 Three Months Ended June 30, 2023 2022 United States $ 19,987 $ 15,025 Rest of world 245 252 Total revenue $ 20,232 $ 15,277 2023 2022 Six Months Ended June 30, 2023 2022 United States $ 37,501 $ 27,719 Rest of world 675 517 Total revenue $ 38,176 $ 28,236

Business Description, Basis o_3

Business Description, Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Impairments of long-lived assets	$ 0	$ 0	$ 0	$ 0
Impairments of goodwill	$ 0	$ 0	$ 0	$ 0
Antidilutive securities excluded from computation of earnings per share, amount	18,885,572	18,885,572	12,474,376	12,474,376

Schedule of Recognized Identifi

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Feb. 28, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Goodwill	$ 6,514		$ 3,205
Surgalign SPV Inc [Member]
Business Acquisition [Line Items]
Inventories		$ 1,589
Equipment		947
Intangible assets		11,155
Net assets acquired		13,691
Goodwill		3,309
Total purchase consideration		$ 17,000

Schedule of Pro forma Financial

Schedule of Pro forma Financial Information of Operations (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Revenues	$ 40,000	$ 31,828
Net loss	$ (3,745)	$ (2,543)

Acquisition of Coflex and CoF_3

Acquisition of Coflex and CoFix Product Lines (Details Narrative) - USD ($) $ in Thousands	Feb. 28, 2023	Jun. 30, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Goodwill		$ 6,514	$ 3,205
Surgalign SPV Inc [Member]
Business Acquisition [Line Items]
Additional inventory	$ 1,589
Additional intangible assets	11,155
Goodwill	3,309
Equity Purchase Agreement [Member] | Surgalign SPV Inc [Member]
Business Acquisition [Line Items]
Aggregate purchase price in cash	17,000
Purchase price in hand	5,000
Additional inventory	500
Additional intangible assets	$ 500

Asset Purchase Agreement (Detai

Asset Purchase Agreement (Details Narrative) - Asset Purchase Agreement [Member] $ in Millions	Jun. 18, 2023 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total purchase price	$ 5
Purchase price escrow, rate	10%

Summary of Revenues from Produc

Summary of Revenues from Product Lines (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Total revenue	$ 20,232	$ 15,277	$ 38,176	$ 28,236
Percentage of total revenue	100%	100%	100%	100%
Orthobiologics [Member]
Disaggregation of Revenue [Line Items]
Total revenue	$ 14,315	$ 12,402	$ 27,866	$ 22,568
Percentage of total revenue	71%	81%	73%	80%
Spinal Implant [Member]
Disaggregation of Revenue [Line Items]
Total revenue	$ 5,917	$ 2,875	$ 10,309	$ 5,659
Percentage of total revenue	29%	19%	27%	20%
Other Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenue			$ 1	$ 9
Percentage of total revenue	0%	0%	0%	0%

Schedule of Allowance for Credi

Schedule of Allowance for Credit Losses (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022
Credit Loss [Abstract]
Beginning balance	$ 621	$ 515	$ 570	$ 552
Provision for expected credit losses	119	106	(49)	191
Write-offs charged against allowance			(11)	(173)
Ending balance	$ 740	$ 621	$ 510	$ 570

Schedule of Inventories (Detail

Schedule of Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 6,359	$ 5,628
Work in process	1,406	798
Finished goods	12,599	10,859
Total	$ 20,364	$ 17,285

Schedule of Property and Equipm

Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 25,378	$ 23,749
Less: accumulated depreciation	(18,503)	(17,964)
Property and equipment, net	6,875	5,785
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	5,597	5,598
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,158	1,043
Computer Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	230	230
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	4,105	4,105
Surgical Instruments [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	12,209	11,266
Assets Not Yet In Service [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,079	$ 1,507

Property and Equipment, Net (De

Property and Equipment, Net (Details Narrative) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Depreciation expenses	$ 0.4	$ 0.3	$ 0.7	$ 0.6

Schedule of Intangible of Asset

Schedule of Intangible of Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$ 11,962	$ 807
Less: accumulated amortization	(1,042)	(463)
Intangible assets, net	10,920	344
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	2,617	807
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	8,100
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$ 1,245

Schedule of Accrued Liabilities

Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Cash compensation/commissions payable	$ 5,455	$ 4,464
Other accrued liabilities	800	1,032
Accrued liabilities	$ 6,255	$ 5,496

Schedule of Long-term Debt (Det

Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Amounts due under the term loan	$ 17,000	$ 12,000
Accrued end-of-term payments	337	216
Less: unamortized debt issuance costs	(228)	(196)
Less: current maturities	(708)	(2,333)
Long-term debt, less issuance costs	$ 16,401	$ 9,687

Debt (Details Narrative)

Debt (Details Narrative) - USD ($) $ in Millions		1 Months Ended
	Feb. 28, 2023	May 31, 2023	Jun. 30, 2023
Line of Credit Facility [Line Items]
Debt instrument interest rate			13.79%
Term Loan And Revolving Credit Facility [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Line of credit, interest rate	1%
Term Loan And Revolving Credit Facility [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Line of credit, interest rate	2.50%
Term Loan Agreement [Member]
Line of Credit Facility [Line Items]
Indebtedness incurred	$ 5
Monthly periodic payment		$ 0.7
Revolving Credit Agreement [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate			9.77%
Line of credit			$ 3

Schedule of Share-based Compens

Schedule of Share-based Compensation, Stock Options Activity (Details) - Equity Option [Member] - 2018 Equity Incentive Plan [Member] - $ / shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares, Outstanding, Balance	3,360,664	3,201,666
Weighted Average Exercise Price Per Share, Outstanding Balance	$ 1.51	$ 1.80
Shares, Granted	130,000	109,164
Weighted Average Exercise Price Per Share, Granted	$ 0.74	$ 0.65
Shares, Cancelled or expired	(75,460)	(443,125)
Weighted Average Exercise Price Per Share, Cancelled or expired	$ 18.61	$ 2.39
Shares, Outstanding, Balance	3,415,204	2,867,705
Weighted Average Exercise Price Per Share, Outstanding Balance	$ 1.49	$ 1.66
Weighted Average Remaining Contractual Term (Years) Outstanding	7 years 8 months 12 days	8 years 4 months 24 days
Shares, Exercisable, Ending Balance	1,438,894	599,063
Weighted Average Exercise Price Per Share, Exercisable Ending Balance	$ 1.93	$ 2.71
Weighted Average Remaining Contractual Term (Years) Exercisable	7 years 3 months 18 days	7 years 9 months 18 days

Schedule of Restricted Stock Ac

Schedule of Restricted Stock Activity (Details) - Restricted Stock Units (RSUs) [Member] - 2018 Equity Incentive Plan [Member] - $ / shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares Outstanding, Balance	3,612,433	2,970,104
Weighted Average Fair Value at Grant Date Per Share, Outstanding Balance	$ 0.88	$ 1.39
Shares Granted	186,831	88,983
Weighted Average Fair Value at Grant Date Per Share, Granted	$ 0.71	$ 0.65
Shares Vested	(22,245)	(244,721)
Weighted Average Fair Value at Grant Date Per Share, Vested	$ 0.65	$ 1.45
Shares Cancelled	(494,121)	(318,807)
Weighted Average Fair Value at Grant Date Per Share, Cancelled	$ 0.54	$ 1.32
Shares Outstanding, Balance	3,282,898	2,495,559
Weighted Average Fair Value at Grant Date Per Share, Outstanding Balance	$ 0.92	$ 1.36

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Millions		6 Months Ended
	Jul. 26, 2023	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average granted date fair value		$ 0.61
2023 Equity Incentive Plan [Member] | Forecast [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation, description	The maximum number of shares of our common stock available for issuance under the 2023 Plan, subject to adjustment pursuant to the terms of the 2023 Plan, is (i) 5,500,000 shares of common stock; (ii) 7,695,812 shares of common stock remaining available for issuance under the 2018 Plan but not subject to outstanding awards under the 2018 Plan as of July 26, 2023; and (iii) up to 6,686,090 shares of common stock subject to awards outstanding under the 2018 Plan as of July 26, 2023 but only to the extent such awards are subsequently forfeited, cancelled, expire, or otherwise terminate without the issuance of such shares of common stock after such date.
Share based compensation, grant	5,500,000
2018 Equity Incentive Plan [Member] | Forecast [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation, grant	7,695,812
Share based compensation, award outstanding	6,686,090
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unvested employee stock options not yet recognized		$ 2
Stock option vested weighted average period		2 years
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unvested employee stock options not yet recognized		$ 1.5
Stock option vested weighted average period		2 years
Equity Option [Member] | 2018 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation, award outstanding		3,415,204	3,360,664	2,867,705	3,201,666

Warrants (Details Narrative)

Warrants (Details Narrative) - Warrant [Member] - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Outstanding and exercisable warrants to purchase	12,187,470	12,187,470
Weighted average exercise price	$ 1.53
Warrants contractual term	3 years 3 months 18 days

Schedule of Future Minimum Rent

Schedule of Future Minimum Rental Payments for Operating Leases (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Remainder of 2023	$ 271
2024	559
2025	470
Total future minimum lease payments	1,300
Less amount representing interest	(92)
Present value of obligations under operating leases	1,208
Less current portion	(488)	$ (458)
Long-term operating lease obligations	$ 720	$ 972

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Operating lease weighted-average remaining lease term	2 years 3 months 18 days		2 years 3 months 18 days
Rent expense	$ 0.1	$ 0.1	$ 0.3	$ 0.3

Schedule of Supplemental Cash F

Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Supplemental Cash Flow Elements [Abstract]
Interest	$ 1,171	$ 667
Fixed assets acquired under finance lease		$ 159

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	Jun. 30, 2023
OrbiMed Advisors LLC [Member]
Ownership percentage	67%

Schedule of Revenues by Geograp

Schedule of Revenues by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	$ 20,232	$ 15,277	$ 38,176	$ 28,236
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	19,987	15,025	37,501	27,719
Rest Of World [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	$ 245	$ 252	$ 675	$ 517

Segment and Geographic Inform_3

Segment and Geographic Information (Details Narrative)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer [Member]
Revenue, Major Customer [Line Items]
Concentration risk, percentage	99%	99%	99%	99%

Subsequent Event (Details Narra

Subsequent Event (Details Narrative) - Investor [Member] - Private Placement [Member] - Subsequent Event [Member] $ / shares in Units, $ in Millions	Jul. 03, 2023 USD ($) $ / shares shares
Subsequent Event [Line Items]
Number of issuance, shares | shares	20,000,000
Shares issued price per share | $ / shares	$ 0.75
Number of issuance, value | $	$ 15